What Is Melanotan II?

Published August 2026 · Patriot Labs Research Team · ~11 min read

The short version

Melanotan II — often written MT-II in the pharmacology literature — is a synthetic peptide built to imitate a natural hormone. The natural hormone is α-MSH, alpha-melanocyte-stimulating hormone, one of the signalling fragments the body cuts out of the proopiomelanocortin precursor. The imitation is a shortened, chemically hardened version of that hormone: seven residues, tied into a ring, with several substitutions that natural peptides do not carry.

Three facts define it, and the rest of this guide unpacks them.

It is cyclic. The ring is a side-chain-to-side-chain amide, a lactam bridge, and that single structural decision is responsible for most of what makes the molecule behave differently from the hormone it copies.

It is non-selective. The IUPHAR/BPS Guide to PHARMACOLOGY lists MT-II with high affinity at MC₁ and MC₄, and the melanocortin receptors it engages are distributed across skin, immune cells, brain, gonads and glandular tissue.¹ A compound that talks to all of them at once is a blunt instrument, and that is a genuine experimental problem rather than a marketing quibble.

It is unapproved and heavily flagged. Melanotan II holds no marketing authorisation, it has attracted enforcement action from national medicines regulators, and there is a real, growing case-report literature describing harms in people who obtained it outside any regulatory system.^7,8,9 That section of this guide is not a formality — it is the part that matters most.

If you want the head-to-head chemistry against its close relative, that is a separate piece: Melanotan II vs PT-141 works through the single functional group that separates them and the binding numbers across all five receptors. This guide stays on Melanotan II itself. If peptide nomenclature is new, start with what peptides are.

Arizona, α-MSH and the hunt for a stable analogue

The chemistry behind Melanotan II came out of a melanotropin research programme at the University of Arizona. In 1989 Al-Obeidi, Hadley, Pettitt and Hruby published Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations in the Journal of the American Chemical Society,⁵ and in the same year Al-Obeidi, Castrucci, Hadley and Hruby published Potent and prolonged-acting cyclic lactam analogs of α-melanotropin: design based on molecular dynamics in the Journal of Medicinal Chemistry.⁴ The titles carry the whole thesis: use computational conformational analysis to decide where to close a ring, then build the ring, and get a molecule that is both more potent and longer-acting than the natural peptide.

That was the design brief. Native α-MSH is a short linear peptide, and short linear peptides are, as a class, easy to destroy — exopeptidases trim them from the ends, endopeptidases cut them in the middle, and their conformational freedom means only a small fraction of the molecules in solution are in a receptor-compatible shape at any instant. The Arizona work attacked both problems at once: constrain the shape, and make the constrained shape resistant to the enzymes.

The potency claim is not rhetorical. The Guide to PHARMACOLOGY lists MT-II at the human MC₁ receptor at pIC₅₀ 9.4 against pIC₅₀ 8.4 for α-MSH itself — a full order of magnitude, in the same database, at the same receptor.¹ At MC₄, MT-II is listed at pK_i 8.2–8.8 against α-MSH at pK_i 7.4–8.0.¹ A designed analogue beating its endogenous template by roughly tenfold at two different receptors is a fair result for a seven-residue molecule.

The broader history of this compound class was later written up by two of the same Arizona figures: Hadley and Dorr's Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization, Peptides 2006;27(4):921–930.⁶ We retrieved that record bibliographically and did not obtain the full text, so we characterise it no further than its title.

What cyclisation actually buys you

This is the part worth reading even if melanocortins are not your field, because the logic generalises to almost every peptide on this site.

Melanotan II is a cyclic lactam heptapeptide. PubChem records it under CID 92432 with the molecular formula C₅₀H₆₉N₁₅O₉.³ The ring is not made by joining the N-terminus to the C-terminus, which is the obvious way to cyclise something. It is made by forming an amide bond between the carboxyl group on an aspartate side chain and the amine group on a lysine side chain, several residues apart. That side-chain-to-side-chain amide is what "lactam bridge" means, and it leaves both ends of the peptide free to carry their own modifications.

Two things follow from closing that ring.

Conformational rigidity. A linear heptapeptide has a rotatable bond at essentially every backbone position, so in solution it is not one shape but an enormous ensemble of shapes interconverting constantly. A receptor binds one of them. Every other conformation the molecule spends time in is wasted. Tying two side chains together removes a large fraction of that conformational space at a stroke, so a much greater proportion of the population sits at or near the binding-competent geometry. In thermodynamic terms you are pre-paying the entropic cost of folding at synthesis time rather than at binding time. That is why the Arizona group ran dynamic simulations first and then chose where to close the ring — the goal was to lock in the shape the receptor already wanted.⁵

Protease resistance. Proteases are shape-selective. A typical endopeptidase has to thread an extended stretch of substrate backbone through a groove and present the scissile bond to the catalytic residues in a specific geometry. A backbone that is stapled into a ring cannot adopt that extended presentation, so the cleavage sites inside the ring become physically hard to reach. Cyclisation is not the only trick used here either: the same molecular class carries an acetylated N-terminus and a C-terminal amide, both of which cap the charged termini that exopeptidases recognise, and a D-amino acid substitution at the position corresponding to phenylalanine 7, since proteases evolved on L-amino acids and handle their mirror images badly. Four independent hardening strategies in one small peptide. Our guide to how peptides degrade covers the failure modes these modifications are defending against.

The design idea has not stopped moving, either. A 2024 paper in Chemistry — A European Journal, 5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II, appears in the current literature as a methods paper using this molecule as a test case for new stapling chemistry.¹⁰ We retrieved the bibliographic record only, so we say nothing about its results — but it does show that MT-II remains a reference scaffold for peptide chemists rather than a closed chapter.

Non-selective, in a family that is everywhere

There are five melanocortin receptors, MC₁ to MC₅. All five are G-protein-coupled receptors and all five are listed with the same principal transduction mechanism: the G_s family, which stimulates adenylyl cyclase and raises intracellular cyclic AMP.¹ They differ not in the second messenger they use but in where they sit and which endogenous ligand they prefer.

Melanotan II is a broad agonist across this family. It is listed with high affinity at MC₁, MC₃, MC₄ and MC₅, with no receptor separated far enough from the rest to be called its primary target. MC₂ is the exception, and for a structural reason rather than a potency one: MC₂ is the ACTH receptor, and ACTH is the only melanocortin it recognises.¹ When any source calls a compound a "non-selective melanocortin agonist", MC₂ is silently excluded from that claim.

Why does non-selectivity matter more here than it would for some other receptor family? Because of the distributions. Look at just two of the five receptor pages:

MC₁ (human gene at 16q24.3) is not confined to pigment cells. The Guide to PHARMACOLOGY records expression in melanoma cells, endothelial cells, neutrophils, macrophages, fibroblasts, dermal papilla cells, pituitary and testis.¹ Mun and colleagues make the same point from the other direction, describing MC1R as "mainly expressed in both melanocytes and leukocytes" and noting that "monocytes and macrophages are known to express the MC1R, which mediates anti-inflammatory effects".² A 2006 Peptides paper by Lam, Perretti and Getting on melanocortin receptor signalling in the RAW264.7 macrophage cell line sits in the same tradition of treating these receptors as immune-cell receptors rather than skin receptors.¹¹

MC₄ (18q21.32) is largely a central receptor — paraventricular, arcuate and dorsomedial hypothalamic nuclei, amygdala, periaqueductal grey, brainstem, spinal cord — but is also listed in pituitary and, again, dermal papilla cells.¹ It is also the receptor where the "everything is just cyclic AMP" story breaks down: alongside G_s, the record lists calcium mobilisation through an incompletely understood pathway and modulation of the inwardly rectifying potassium channel Kir7.1.¹ Two receptors from the same family, both nominally G_s-coupled, with materially different downstream repertoires.

So a non-selective melanocortin agonist added to any preparation more complex than a single-receptor transfected line is very likely engaging more than one receptor, in more than one cell type, through more than one downstream branch. That is the pharmacological significance, and it is a limitation rather than a feature.

One further wrinkle: this family has endogenous antagonists, which is unusual. Agouti and agouti-related protein act as inverse agonists at melanocortin receptors, with AGRP listed at pIC₅₀ 9.3 at MC₄.¹ Baseline melanocortin tone in a tissue is therefore set by the balance between agonist and inverse agonist, not by agonist availability alone — which means adding an exogenous agonist perturbs a two-sided system.

For how this profile compares with the close structural relative PT-141 (bremelanotide), including the full affinity table across all five receptors, see the comparison guide.

Melanogenesis as cell biology

Pigment biology is the reason this receptor family is named the way it is, and it is worth describing properly — as a signalling cascade in melanocytes, which is the level at which it has actually been characterised.

Mun, Kim and Shin's 2023 review in the International Journal of Molecular Sciences sets out the chain step by step. "When agonistic ligands bind to MC1R, the Gαs protein is separated, and MC1R activates adenylyl cyclase, which leads to the production of cAMP."² Then: "In melanocytes, cAMP activates protein kinase A (PKA) and triggers downstream signaling pathways that activate different effector pathways, including the CREB and MITF networks."² And finally: "These pathways lead to the increased expression of tyrosinase and dopachrome tautomerase, two enzymes that are involved in melanin synthesis".²

Read that as a transcriptional cascade rather than a switch. The receptor does not manufacture pigment; it raises cyclic AMP, which activates a kinase, which activates transcription factors, one of which — MITF, the microphthalmia-associated transcription factor — is the master regulator of the melanocyte differentiation programme. The enzymes that do the chemistry, tyrosinase chief among them, are downstream gene products. Everything in that chain is measurable in a cultured cell: cyclic AMP by immunoassay, PKA activity by substrate phosphorylation, MITF and TYR transcript levels by qPCR, tyrosinase by activity assay.

The same review describes the eumelanin arm of the output directly: cAMP "activates microphthalmia transcription factor (MITF) expression, which induces the expression of enzymes for eumelanin production", and eumelanin "protects against UV light by absorbing and scattering it, scavenging free radicals and reactive oxygen species".² That is the functional logic of the pathway in cell-biological terms — a receptor that upregulates synthesis of a radical-scavenging biopolymer.

The opposing arm is where the classical eumelanin/pheomelanin framing comes from. Mun and colleagues state that "melanocortins stimulate MC1R signaling, while ASIP inhibits MC1R signaling and reduces cAMP levels",² and the Guide to PHARMACOLOGY lists agouti and AGRP as inverse agonists at these receptors.¹ The standard textbook description is that low MC1R signalling tone shifts melanocyte output away from eumelanin and toward pheomelanin, the lighter, sulphur-containing pigment class. We did not retrieve a full text stating that switch explicitly in this task, so we flag it as the conventional model rather than something we are sourcing here. What we can source is the direction of control: melanocortin agonism raises cyclic AMP and eumelanin gene expression, and ASIP does the reverse.²

Worth noting the contrast with a much smaller molecule from the same parent hormone. KPV is the C-terminal tripeptide fragment of α-MSH — three residues rather than seven, no ring, and no meaningful melanocortin receptor agonism. Same ancestor, opposite design philosophy: Melanotan II keeps and hardens the receptor-binding core, KPV discards it and keeps the tail. That the two are studied for entirely different things is a good reminder that "α-MSH-derived" is a statement about ancestry, not about pharmacology.

Melanotan II against native α-MSH

Affinity values as listed on the IUPHAR/BPS Guide to PHARMACOLOGY MC₁ and MC₄ receptor pages for human receptors.¹ pIC₅₀ and pK_i are different measurements from different assay designs; compare down a column, not across the two affinity rows.

The safety and regulatory record

This is the section that would be dishonest to soften, so it is reported plainly and with sources.

The literature exists and it is not small. A Europe PMC search for melanotan run on 10 August 2026 returned a hit count of 753 records.¹⁰ A striking proportion of the most recent entries are clinical case reports and public-health commentary rather than pharmacology. Among the records returned in that search: Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use (JAAD Case Reports, 2026); Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? (International Journal of Oral and Maxillofacial Surgery, 2025); Pyoderma Gangrenosum Secondary to Melanotan (Cureus, 2025); Depigmented Facial and Neck Patches Following Melanotan Use in a Patient With Atopic Dermatitis and Alopecia Areata (Clinical and Experimental Dermatology, 2026); Unregulated Melanotan Use Promoted via Social Media: Emerging Dermatologic and Public Health Risks (International Journal of Dermatology, 2026); and An overview of benefits and risks of chronic melanocortin-1 receptor activation (Journal of the European Academy of Dermatology and Venereology, 2025).¹⁰ These are bibliographic records retrieved from that search; we did not obtain their full texts, so we report their titles and nothing more.

A retrieved case report states the position directly. Bonchev's 2026 case report in Life describes Melanotan II as "an unlicensed synthetic peptide analog belonging to the melanocortin hormone family" and states that "Melanotan II remains unregulated, and its use is associated with a range of potential adverse effects".⁷ Its literature summary is blunt: "Multiple case reports have described serious adverse effects linked to the use of Melanotan II, including the development of exogenous hypercortisolism, rhabdomyolysis, priapism and acute renal failure."⁷ The same paper records that regulatory agencies "including the U.S. Food and Drug Administration (FDA), the Health Products Regulatory Authority (HPRA) in Ireland, and the Therapeutic Goods Administration (TGA) in Australia, have issued warnings regarding the potential significant safety risks", and notes that the material in that case was obtained from an online retailer specialising in research peptides.⁷

Australia. The TGA has published a public advisory on melanotan products, which records that the agency issued "27 infringement notices, totalling $101,412, to a NSW-based individual for the alleged unlawful supply of Melanotan II".⁸ That is enforcement, not a caution.

United Kingdom. A written answer from the Department of Health, answered 16 June 2014 to written question 200340, responds to a query about "the sale of the unlicensed drug Melanotan". The department confirmed that melanotan products hold no UK marketing authorisation and that their sale breaches regulatory requirements, that the MHRA had suspended more than 100 illegal websites trading in melanotan within a twelve-month period, and that as of 12 June 2014 the agency had received 22 reports of adverse drug reactions describing 93 adverse events in total — while noting that a causal link with the product was not established.⁹

Two honest observations about that last figure. Spontaneous adverse-event reporting is passive and under-reports heavily, so 22 reports is a floor and not an estimate. And the department's own caveat about causality is the correct one: a report is an association in time, not a demonstrated cause. Both things can be true — the number is unreliable in one direction and uninterpretable in the other — and it is still a signal that regulators acted on.

None of this is a statement about the molecule's receptor pharmacology, which is the subject of the rest of this guide. It is a statement about what happens when a potent, non-selective agonist for a receptor family expressed across half the body's tissues circulates outside any regulatory system. Those are separate facts and both belong in an honest explainer.

What the evidence does not establish

It does not establish receptor-level attribution for anything. Melanotan II engages at least four melanocortin receptors with affinities inside about one order of magnitude of each other.¹ In any preparation expressing more than one of them, an observed response cannot be assigned to a specific receptor without selective antagonists, knockdown, knockout or single-receptor transfected backgrounds. Most published melanocortin affinity data is generated in exactly those artificial single-receptor systems for this reason.

The affinity values are not directly comparable across receptors. The MC₁ figures cited here are pIC₅₀ and the MC₄ figures are pK_i.¹ These are different quantities from different assay designs, and IC₅₀ in particular depends on the radioligand concentration used. Comparing MT-II to α-MSH within one receptor page is reasonable. Comparing MT-II at MC₁ to MT-II at MC₄ across pages is not.

Species differences are documented in this exact family. The Guide to PHARMACOLOGY notes that human MC₁ is "supersensitive" to melanocortin peptides compared with the mouse receptor.¹ That is a specific, named translation hazard for anyone moving between rodent and human receptor systems here.

The pigment-pathway description is a pathway description, not an outcome. Everything in the melanogenesis section is receptor coupling and gene expression in melanocytes as described in a review.² Signalling cascades are several inferential steps removed from organism-level statements, and this guide does not take those steps.

We did not source the pheomelanin arm. The eumelanin side of the pathway is quoted from a retrieved full text.² The classical eumelanin-to-pheomelanin switch is stated here as the conventional model only, because we did not retrieve a source for it in this task.

Most of the safety literature is case reports. Case reports are single observations without controls, without denominators, and usually without analytical confirmation of what the material actually contained. They are the appropriate way to raise a signal and a poor way to estimate risk. The 753-record Europe PMC hit count¹⁰ reflects a literature, not a quantified hazard. Where we list those titles we have deliberately not characterised their findings, because we retrieved records rather than texts.

Nothing here describes a use. No section of this guide describes an application in a person, an amount, a schedule or an outcome, and no part of it should be read as implying one.

What this means at the bench

Three practical consequences follow from the pharmacology above.

Choose the system to match the question. Because MT-II is non-selective, a multi-receptor preparation cannot answer a single-receptor question. If the point of an experiment is MC₁ signalling specifically, that argues for a transfected single-receptor line or a receptor-selective antagonist control, not for a primary tissue that expresses three subtypes at once.¹

Cyclic peptides are not indestructible. The lactam ring and the terminal caps defend against proteolysis; they do nothing about oxidation of the tryptophan residue, about aggregation, or about freeze–thaw damage. The stability advantage designed into this molecule is specific to one degradation route, and the others are covered in how peptides degrade.

Identity checking matters unusually much for this compound. Melanotan II differs from its nearest structural neighbour by a single functional group at the C-terminus — roughly one mass unit in a molecule of over a thousand. A purity percentage from an HPLC trace does not distinguish them; mass spectrometry does. That is a general argument for reading the mass-spec section of a certificate of analysis rather than the purity headline, and a specific one here. Both compounds are stocked as research materials: PT-141 is the neighbour in question.

Frequently asked questions

What kind of molecule is Melanotan II? A synthetic cyclic lactam heptapeptide analogue of α-MSH. PubChem records CID 92432 with the molecular formula C₅₀H₆₉N₁₅O₉.³ The ring is formed between an aspartate side chain and a lysine side chain rather than through the backbone termini, which leaves both ends free to carry their own modifications.

Why does cyclisation make a peptide more potent and more stable? Two separate mechanisms. Rigidity: constraining the backbone removes conformations that cannot bind, so more of the molecules in solution are already in a receptor-compatible shape. Protease resistance: peptidases need an extended backbone geometry to cleave, and a ring cannot present one. The 1989 Arizona papers set out the design logic of picking the ring position by simulation first.^4,5

Why is Melanotan II called non-selective? Because it is listed as a high-affinity agonist at MC₁, MC₃, MC₄ and MC₅ without one receptor dominating — pIC₅₀ 9.4 at MC₁ and pK_i 8.2–8.8 at MC₄, for instance.¹ MC₂ is excluded because it recognises ACTH only.¹

How is melanogenesis described at the pathway level? Agonist binding at MC1R separates Gαs and activates adenylyl cyclase, raising cyclic AMP; cyclic AMP activates PKA; PKA feeds the CREB and MITF networks; those raise expression of tyrosinase and dopachrome tautomerase.² Agouti signalling protein runs the pathway in reverse by inhibiting MC1R signalling and lowering cyclic AMP.²

How does it differ from PT-141? By a single functional group at the C-terminus, which shifts the receptor profile. The full comparison, including the binding table across all five receptors, is in Melanotan II vs PT-141.

What have regulators actually said? Australia's TGA has published enforcement action — 27 infringement notices totalling $101,412 against one New South Wales individual for alleged unlawful supply of Melanotan II.⁸ A UK Department of Health written answer of 16 June 2014 confirmed no UK marketing authorisation, recorded more than 100 illegal websites suspended by the MHRA in twelve months, and 22 adverse drug reaction reports describing 93 adverse events, causality not established.⁹ A 2026 case report additionally names the FDA and Ireland's HPRA among agencies that have issued warnings.⁷

Is Melanotan II approved for human use? No. It holds no marketing authorisation in any jurisdiction we checked, and the material described here is sold strictly for in-vitro research and laboratory use only, not for human or veterinary consumption.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.